Pharma BD Deal Intelligence
Pfizer's $5.4 billion cash acquisition of Global Blood Therapeutics gave it Oxbryta, the first-in-class sickle cell disease therapy, plus inclacumab and GBT601 in the pipeline—a straightforward bolt-on to build out a rare hematology franchise beyond its existing portfolio.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Pfizer acquired Global Blood Therapeutics for approximately $5.4 billion ($68.50 per share in cash), gaining Oxbryta (voxelotor), a first-in-class HbS polymerization inhibitor approved for sickle cell disease, along with inclacumab (Phase III) and GBT601 pipeline assets.
The SCD landscape spans four distinct MOA classes, each with rapidly shifting commercial dynamics. HbS polymerization inhibitors: Oxbryta (voxelotor, Pfizer/GBT) was approved November 2019 as the first disease-modifying small molecule but was withdrawn globally September 2024 due to post-marketing safety signals (excess deaths, vaso-occlusive crises), collapsing the franchise; pre-withdrawal Oxbryta generated $328M in 2023 Pfizer revenue. P-selectin inhibitors: Adakveo (crizanlizumab, Novartis) was FDA-approved November 2019 for VOC reduction but had EU marketing authorization withdrawn May 2023 after the STAND confirmatory trial failed to replicate SUSTAIN efficacy. Cytotoxic/HbF-induction backbone: hydroxyurea (generic; branded Droxia, Bristol Myers Squibb and Siklos, Medunik/Addmedica) remains first-line standard of care. Amino acid modulator: Endari (L-glutamine oral powder, Emmaus Life Sciences, approved July 2017). Gene/cell therapies: Casgevy (exagamglogene autotemcel, Vertex/CRISPR Therapeutics, CRISPR-edited BCL11A) and Lyfgenia (lovotibeglogene autotemcel, bluebird bio, lentiviral beta-globin gene addition) received concurrent FDA approval December 2023, pricing at $2.2M and $3.1M respectively with severely restricted capacity. Commercial read: the disease-modifying small-molecule niche has effectively vacated post-Oxbryta withdrawal; gene therapy competes for severe populations while hydroxyurea plus supportive care remains the commercial floor. Pfizer's SCD franchise value is materially impaired.
Pfizer to acquire GBT for $68.50/share to build SCD franchise around Oxbryta. Part of Pfizer Inc.'s $5.4B deal to acquire Global Blood Therapeutics Inc..
Acquisition closed. Oxbryta and SCD pipeline transferred to Pfizer rare disease.
Pfizer reported $328M global Oxbryta sales in first full year of ownership. Reflects financial performance following Pfizer Inc.'s $5.4B acquisition of Global Blood Therapeutics Inc..
Voluntary global withdrawal after clinical data showed elevated mortality risk. Part of Pfizer Inc.'s $5.4B deal to acquire Global Blood Therapeutics Inc..
Pfizer voluntarily withdrew Oxbryta (voxelotor) globally on Sep 25, 2024 after post-marketing data showed imbalance in vaso-occlusive crises and deaths. $5.4B GBT acquisition thesis impaired.
On Aug 15, 2025 Pfizer reported the Phase 3 THRIVE-131 study of inclacumab (P-selectin inhibitor, IV q12w; 241 participants aged 16+) did not meet its primary endpoint of reducing vaso-occlusive crises vs placebo over 48 weeks -- the second major failure among GBT-legacy pipeline assets.
FDA placed a partial clinical hold on osivelotor (GBT601, next-gen HbS polymerization inhibitor) in Dec 2024 barring new enrollment. In 2025 FDA allowed studies to proceed outside sub-Saharan Africa; Pfizer resumed enrolling new Phase 3 participants in Q1 2026. Osivelotor is the last untainted GBT-legacy SCD asset after Oxbryta's withdrawal and inclacumab's Phase 3 failure.
See timeline for full assessment. Assessment of Pfizer Inc.'s $5.4B acquisition of Global Blood Therapeutics Inc. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Global Blood Therapeutics Inc. (this deal) | 2022 | $5.4B | 29 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2022 deals · Pfizer Inc. deals · Hematology deals